表紙
市場調査レポート

Novogen Limited :製品パイプライン分析

Novogen Limited - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224651
出版日 ページ情報 英文 28 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
Novogen Limited :製品パイプライン分析 Novogen Limited - Product Pipeline Review - 2015
出版日: 2015年11月30日 ページ情報: 英文 28 Pages
概要

Novogen Limited は、2大薬剤技術プラットフォームを持っているオーストラリアのバイオテクノロジー企業です。それは、癌細胞骨格を標的として黒色腫、前立腺ガン、神経芽細胞腫などの治療のために開発された反トロポミオシン抗体(ATM)と、癌幹細胞を標的として、卵巣癌、神経膠芽腫の治療のために開発されたスーパーベンゾピラン (SBP)です。

当レポートでは、Novogen Limited における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Novogen Limitedの基本情報

Novogen Limitedの概要

  • 主要情報
  • 企業情報

Novogen Limited :R&Dの概要

  • 主な治療範囲

Novogen Limited :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Novogen Limited :パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Novogen Limited :薬剤プロファイル

  • ATM-3507
  • TR-100
  • Trilexium
  • Trx-7
  • Small Molecules for CNS and Muscular Dystrophy Diseases

Novogen Limited :パイプライン分析

  • 分子タイプ別

Novogen Limited :最近のパイプライン動向

Novogen Limited :休止中のプロジェクト

Novogen Limited :企業発表

Novogen Limited :本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07829CDB

Summary

Global Markets Direct's, 'Novogen Limited - Product Pipeline Review - 2015', provides an overview of the Novogen Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novogen Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Novogen Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Novogen Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Novogen Limited's pipeline products

Reasons to buy

  • Evaluate Novogen Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Novogen Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Novogen Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Novogen Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novogen Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Novogen Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Novogen Limited Snapshot
    • Novogen Limited Overview
    • Key Information
    • Key Facts
  • Novogen Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Novogen Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Novogen Limited - Pipeline Products Glance
    • Novogen Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Novogen Limited - Drug Profiles
    • ATM-3507
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TR-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Trilexium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRXE-0025
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for CNS and Muscular Dystrophy Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Novogen Limited - Pipeline Analysis
    • Novogen Limited - Pipeline Products by Route of Administration
    • Novogen Limited - Pipeline Products by Molecule Type
  • Novogen Limited - Recent Pipeline Updates
  • Novogen Limited - Dormant Projects
  • Novogen Limited - Company Statement
  • Novogen Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Novogen Limited, Key Information
  • Novogen Limited, Key Facts
  • Novogen Limited - Pipeline by Indication, 2015
  • Novogen Limited - Pipeline by Stage of Development, 2015
  • Novogen Limited - Monotherapy Products in Pipeline, 2015
  • Novogen Limited - Partnered Products in Pipeline, 2015
  • Novogen Limited - Partnered Products/ Combination Treatment Modalities, 2015
  • Novogen Limited - Preclinical, 2015
  • Novogen Limited - Discovery, 2015
  • Novogen Limited - Pipeline by Route of Administration, 2015
  • Novogen Limited - Pipeline by Molecule Type, 2015
  • Novogen Limited - Recent Pipeline Updates, 2015
  • Novogen Limited - Dormant Developmental Projects,2015
  • Novogen Limited, Subsidiaries

List of Figures

  • Novogen Limited - Pipeline by Top 10 Indication, 2015
  • Novogen Limited - Pipeline by Stage of Development, 2015
  • Novogen Limited - Monotherapy Products in Pipeline, 2015
  • Novogen Limited - Pipeline by Top 10 Molecule Type, 2015
Back to Top